127 related articles for article (PubMed ID: 38433368)
1. Discovery of Selective and Potent ATR Degrader for Exploration its Kinase-Independent Functions in Acute Myeloid Leukemia Cells.
Wang Y; Wang R; Zhao Y; Cao S; Li C; Wu Y; Ma L; Liu Y; Yao Y; Jiao Y; Chen Y; Liu S; Zhang K; Wei M; Yang C; Yang G
Angew Chem Int Ed Engl; 2024 Apr; 63(17):e202318568. PubMed ID: 38433368
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Alfayomy AM; Ashry R; Kansy AG; Sarnow AC; Erdmann F; Schmidt M; Krämer OH; Sippl W
Eur J Med Chem; 2024 Mar; 267():116167. PubMed ID: 38308949
[TBL] [Abstract][Full Text] [Related]
3. Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
Liu W; Bai Y; Zhou L; Jin J; Zhang M; Wang Y; Lin R; Huang W; Ren X; Ma N; Zhou F; Wang Z; Ding K
Eur J Med Chem; 2024 Jan; 264():115974. PubMed ID: 38007910
[TBL] [Abstract][Full Text] [Related]
4. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
5. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract][Full Text] [Related]
7. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
9. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.
Qi W; Xu X; Wang M; Li X; Wang C; Sun L; Zhao D; Sun L
Biochem Pharmacol; 2019 Jun; 164():273-282. PubMed ID: 31014753
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.
Huang L; Shao J; Lai W; Gu H; Yang J; Shi S; Wufoyrwoth S; Song Z; Zou Y; Xu Y; Zhu Q
Eur J Med Chem; 2024 Mar; 267():116159. PubMed ID: 38325007
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract][Full Text] [Related]
14. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
15. Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia.
Liu L; Hu X; Feng J; Lei A; Huang S; Liu X; Liu H; Luo L; Yao W
Anticancer Drugs; 2024 Mar; 35(3):251-262. PubMed ID: 38164802
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a PROTAC degrader for METTL3-METTL14 complex.
Du W; Huang Y; Chen X; Deng Y; Sun Y; Yang H; Shi Q; Wu F; Liu G; Huang H; Ding J; Huang X; Xu S
Cell Chem Biol; 2024 Jan; 31(1):177-183.e17. PubMed ID: 38194973
[TBL] [Abstract][Full Text] [Related]
17. An MDM2 degrader for treatment of acute leukemias.
Marcellino BK; Yang X; Ümit Kaniskan H; Brady C; Chen H; Chen K; Qiu X; Clementelli C; Herschbein L; Li Z; Elghaity-Beckley S; Arandela J; Kelly B; Hoffman R; Liu J; Xiong Y; Jin J; Shih AH
Leukemia; 2023 Feb; 37(2):370-378. PubMed ID: 36309559
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
[TBL] [Abstract][Full Text] [Related]
19. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
20. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Li Y; Yang J; Aguilar A; McEachern D; Przybranowski S; Liu L; Yang CY; Wang M; Han X; Wang S
J Med Chem; 2019 Jan; 62(2):448-466. PubMed ID: 30525597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
